TY - JOUR
T1 - Quality of life in patients with Graves' ophthalmopathy is markedly decreased
T2 - Measurement by the medical outcomes study instrument
AU - Gerding, M. N.
AU - Terwee, C. B.
AU - Dekker, F. W.
AU - Koornneef, L.
AU - Prummel, M. F.
AU - Wiersinga, W. M.
PY - 1997
Y1 - 1997
N2 - To assess the impact of Graves' ophthalmopathy (GO) on quality of life using a general questionnaire, we performed a descriptive study on consecutive ophthalmopathy patients. We included 70 consecutive, euthyroid patients (age >18 years, 50 females, 20 males, mean ± SD age 53 ± 13 years) with varying degrees of severity of GO. General quality of life was assessed with the brief survey (24 questions) from the Medical Outcomes Study (MOS- 24), and three subscales of the Sickness Impact Profile (SIP). In comparison with a large published reference group, low scores on the MOS-24 were found. Mean ± SD scores (difference from reference group) were: physical functioning 58 ± 31 (-28), role functioning 72 ± 40 (-15), social functioning 78 ± 25 (-14), mental health 67 ± 18 (-10), health perceptions 46 ± 22 (-26), and bodily pain 68 ± 28 (-6). MOS-24 and SIP scores did not correlate with the duration, severity, or activity of the ophthalmopathy. In conclusion, we have shown that mild to moderately severe GO has a large influence on the quality of life of these patients. The negative impact on well-being seems not to be related to the usual clinical assessment. These results underscore the need for quality-of-life measurements in clinical trials.
AB - To assess the impact of Graves' ophthalmopathy (GO) on quality of life using a general questionnaire, we performed a descriptive study on consecutive ophthalmopathy patients. We included 70 consecutive, euthyroid patients (age >18 years, 50 females, 20 males, mean ± SD age 53 ± 13 years) with varying degrees of severity of GO. General quality of life was assessed with the brief survey (24 questions) from the Medical Outcomes Study (MOS- 24), and three subscales of the Sickness Impact Profile (SIP). In comparison with a large published reference group, low scores on the MOS-24 were found. Mean ± SD scores (difference from reference group) were: physical functioning 58 ± 31 (-28), role functioning 72 ± 40 (-15), social functioning 78 ± 25 (-14), mental health 67 ± 18 (-10), health perceptions 46 ± 22 (-26), and bodily pain 68 ± 28 (-6). MOS-24 and SIP scores did not correlate with the duration, severity, or activity of the ophthalmopathy. In conclusion, we have shown that mild to moderately severe GO has a large influence on the quality of life of these patients. The negative impact on well-being seems not to be related to the usual clinical assessment. These results underscore the need for quality-of-life measurements in clinical trials.
UR - http://www.scopus.com/inward/record.url?scp=0031448752&partnerID=8YFLogxK
U2 - https://doi.org/10.1089/thy.1997.7.885
DO - https://doi.org/10.1089/thy.1997.7.885
M3 - Article
C2 - 9459632
SN - 1050-7256
VL - 7
SP - 885
EP - 889
JO - Thyroid
JF - Thyroid
IS - 6
ER -